CA-GLOBAL-CLEAN-ENERGY
3.1.2022 15:02:07 CET | Business Wire | Press release
Global Clean Energy Holdings, Inc., (OTCQX: GCEH), a vertically integrated renewable fuels company, today announced that it has acquired Camelina Company España S.L. (CCE), Europe’s largest camelina crop innovator and seed producer headquartered in Madrid, Spain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005073/en/
CCE has received international acclaim for more than 10 years by developing world class intellectual property (IP) in camelina to support a sustainable biofuels value chain. CCE’s IP includes superior genetics, breeding capabilities, high quality planting seed, advanced agronomic research, and knowledge to support the cultivation of camelina by contract farmers. CCE, together with Sustainable Oils, Inc. (SusOils), also a wholly owned subsidiary of GCE, will further enhance the company's portfolio of patented camelina genetics. CCE and SusOils have been collaborating for some time to expand and harmonize their collective research and development activities. The combined capabilities will accelerate the development of proprietary germplasm and varieties of camelina that will provide third-party contract camelina growers in North America, Western Europe and South America with additional revenue opportunities by sustainably increasing their fallow crop rotation options.
“The addition of CCE to our family of companies and its synergy with SusOils further advances our goal of increasing the commercial value of camelina through improved agronomics and plant genetics. Together, CCE and SusOils will build on our combined decades of camelina research and development activities that are focused on improving yield, reducing growing time, modifying plant oil chemistry to enhance biorefinery efficiency, and improving livestock feed qualities of camelina meal,” said Richard Palmer, GCE’s President & CEO “This acquisition demonstrates our ongoing commitment to investing both domestically and internationally in the science, infrastructure and farmer education necessary to deliver high-quality camelina feedstocks to satisfy the growing worldwide demand for renewable diesel and sustainable aviation fuels while not displacing food crops or impacting food security. This acquisition provides an established launching pad for our rapid expansion into Europe and South America.”
Established in 2010, CCE is Europe’s largest camelina crop innovator and seed producer. In 2013, it was the first global company to receive a sustainability certification from the Roundtable on Sustainable Biomaterials (RSB ), a global sustainability standard and certification system for biofuels and biomaterials production. The company has extensive expertise in camelina production along the complete value chain, having supplied sustainable and certified camelina oil for aviation biofuel production, as well as camelina meal, a high-quality plant based protein source for the livestock feed industry. The company maintains an ongoing plant breeding program with more than 600 camelina germplasm lines and owns nine proprietary camelina varieties, which enables the sustainable introduction of camelina in different crop rotations without displacing any primary crops.
“We are excited by the significant synergies that exist between CCE, GCE and SusOils,” said Yuri Herreras Yambanis, Director, CCE. “Combining the knowledge and expertise of our organizations provides us the opportunity to further advance camelina research and production in ways that deliver profitable and sustainable advantages for both regenerative agriculture and the renewable fuels industry.”
Camelina is an essential part of the feedstock plan for GCE’s integrated farm-to-fuels strategy. In early 2022, GCE will open a newly renovated renewable diesel biorefinery in Bakersfield, California, and supply ExxonMobil up to 220 million gallons annually of renewable diesel under a pair of long-term purchase agreements.
About Global Clean Energy Holdings, Inc.
Global Clean Energy Holdings, Inc. (“GCE” or “GCEH”) is a vertically integrated renewable fuels company specializing in nonfood-based feedstocks used for the production of advanced biofuels and biomaterials. With a footprint that stretches from the laboratory to the farm gate through to biorefinery production, GCE’s farm-to-fuels value chain integration provides unrivaled access to reliable, ultra-low carbon feedstocks. When online, the Bakersfield Biorefinery will be the only facility of its type, processing both traditional feedstocks as well as domestically produced camelina oil into sustainable, ultra-low carbon fuels in California. To learn more, visit gceholdings.com.
About Camelina Company España S.L.
Camelina Company España S.L. (CCE) has developed a sustainable camelina value chain: from breeding and planting seed production to agronomic expansion and camelina processing for advanced biofuel production. CCE introduces camelina into existing crop rotations without any food displacement - as a catch crop or replacement of traditional fallow periods - employing its proprietary camelina varieties and prediction models to optimize its elite varieties in different cropping systems, primarily in Europe and South America. CCE was established in 2010 and is headquartered in Madrid, Spain. To learn more, visit camelinacompany.es.
About Sustainable Oils, Inc.
Sustainable Oils, Inc. (SusOils), GCEH’s wholly owned plant science subsidiary, owns an industry-leading portfolio of intellectual property, including patents and production know-how, to produce its proprietary varieties of camelina, a nonfood based ultra-low carbon biofuels feedstock. SusOils’ corporate headquarters are located in Great Falls, Montana. To learn more, visit susoils.com.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Global Clean Energy Holdings, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements are forward-looking statements and are subject to a number of risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005073/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom